Response and duration of response
| Efficacy end points . | Result . |
|---|---|
| Platelet elevation, n/N (%) | |
| Platelet count ≥ 50 000/μL at least once | 254/299 (85)* |
| Platelet elevation by stratification variables, n/N (%) | |
| Splenectomized | 92/115 (80) |
| Nonsplenectomized | 162/184 (88) |
| Baseline concomitant ITP medications | |
| Yes | 86/100 (86) |
| No | 168/199 (84) |
| Baseline platelets | |
| < 30 000/μL | 167/208 (80) |
| 30 000/μL to 50 000/μL | 51/52 (98) |
| > 50 000/μL | 36/39 (92) |
| Median no. of cumulative wk with platelets ≥ 50 000/μL and 2 × baseline | |
| All patients (n = 298)† | 44‡ |
| Patients on study for 26 wk (n = 253) | 17 |
| Patients on study for 52 wk (n = 218) | 35 |
| Patients on study for 104 wk (n = 147) | 73 |
| Patients on study for 156 wk (n = 32) | 109 |
| Efficacy end points . | Result . |
|---|---|
| Platelet elevation, n/N (%) | |
| Platelet count ≥ 50 000/μL at least once | 254/299 (85)* |
| Platelet elevation by stratification variables, n/N (%) | |
| Splenectomized | 92/115 (80) |
| Nonsplenectomized | 162/184 (88) |
| Baseline concomitant ITP medications | |
| Yes | 86/100 (86) |
| No | 168/199 (84) |
| Baseline platelets | |
| < 30 000/μL | 167/208 (80) |
| 30 000/μL to 50 000/μL | 51/52 (98) |
| > 50 000/μL | 36/39 (92) |
| Median no. of cumulative wk with platelets ≥ 50 000/μL and 2 × baseline | |
| All patients (n = 298)† | 44‡ |
| Patients on study for 26 wk (n = 253) | 17 |
| Patients on study for 52 wk (n = 218) | 35 |
| Patients on study for 104 wk (n = 147) | 73 |
| Patients on study for 156 wk (n = 32) | 109 |